fbpx

RAMP-301 | NCT06072781

The RAMP-301 trial will assess the safety and efficacy of the combination of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment options (ICT) in patients with recurrent Low-grade Serous Ovarian Cancer (LGSOC) who have progressed on a prior platinum-based [...]

RAMP-301 | NCT060727812024-07-19T11:32:01+10:00

DOMENICA | NCT05201547

The primary objective of this study is to evaluate progression-free survival (PFS) by blinded independent central review (BICR) in patients treated in a first line setting with chemotherapy (paclitaxel and carboplatin) versus dostarlimab.

DOMENICA | NCT052015472024-07-09T16:59:53+10:00

EPOCH | NCT05619913

EPOCH is a Phase II open label international clinical trial, which seeks to improve outcomes in women with tubo-ovarian or uterine carcinosarcoma by providing patients with access to a treatment that offers a greater degree of clinical benefit compared [...]

EPOCH | NCT056199132024-07-09T17:00:21+10:00

PARAGON-II | ACTRN12621000639820

PARAGON-II is a trial investigating whether a combination of two drugs (letrozole with alpelisib or letrozole with ribociclib) is an active treatment for a range of advanced gynaecological cancers that expresses hormone receptors.

PARAGON-II | ACTRN126210006398202024-07-09T17:00:40+10:00

ADELE | ACTRN12621000273886

ADELE is a randomised phase 2 trial testing the effect of ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer.  

ADELE | ACTRN126210002738862024-07-09T17:00:50+10:00

ENDO-3 | NCT04073706

ENDO-3 is a randomised controlled trial that compares sentinel lymph node dissection, a commonly performed procedure for the surgical staging of endometrial cancer, to no node dissection. The outcomes from this trial will provide high-level evidence on sentinel lymph node [...]

ENDO-3 | NCT040737062024-07-09T17:00:57+10:00

HyNOVA | ACTRN12621000269831

HyNOVA is a randomised study comparing hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer.

HyNOVA | ACTRN126210002698312024-07-09T17:01:27+10:00

IGNITE | ACTRN12619001185156P

IGNITE is testing how effective adavosertib treatment is for patients with relapsed high grade serous or endometrioid ovarian cancer with particular genetic faults, which alter how tumour cells respond to treatment.

IGNITE | ACTRN12619001185156P2024-07-09T17:01:43+10:00
Go to Top